In Stage 1 of the OUTMATCH study, researchers found that treating children as young as 1 year old who have multiple food allergies with omalizumab for 16 weeks was more effective than a placebo. This treatment helped increase the amount of peanut and other common food allergens that these children could tolerate without having a reaction. This work was funded by the NIH and led to the approval of omalizumab (Xolair) for food allergy children and adults to be used in allergy clinics throughout the US. Don't be afraid to feed your babies, and if they do develop a food allergy- there are now treatments out there that can be tailored for you.
Omalizumab for the Treatment of Multiple Food Allergies.
